Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial

Abstract Background Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global...

Full description

Bibliographic Details
Main Authors: Philippe Bégin, Jeannie Callum, Nancy M. Heddle, Richard Cook, Michelle P. Zeller, Alan Tinmouth, Dean A. Fergusson, Melissa M. Cushing, Marshall J. Glesby, Michaël Chassé, Dana V. Devine, Nancy Robitalle, Renée Bazin, Nadine Shehata, Andrés Finzi, Allison McGeer, Damon C. Scales, Lisa Schwartz, Alexis F. Turgeon, Ryan Zarychanski, Nick Daneman, Richard Carl, Luiz Amorim, Caroline Gabe, Martin Ellis, Bruce S. Sachais, Kent Cadogan Loftsgard, Erin Jamula, Julie Carruthers, Joanne Duncan, Kayla Lucier, Na Li, Yang Liu, Chantal Armali, Amie Kron, Dimpy Modi, Marie-Christine Auclair, Sabrina Cerro, Meda Avram, Donald M. Arnold
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Trials
Subjects:
Convalescent plasma
SARS-CoV-2
Coronavirus
COVID-19
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-021-05235-3

Internet

https://doi.org/10.1186/s13063-021-05235-3

Similar Items